NovaBridge Biosciences NBP
NASDAQ NBP
$1.37 -0.05 (-3.86%)
At close: Oct 21, 2026 · 4:00 PM EDT

NovaBridge Biosciences (NBP) Current Deferred Revenue (2018 - 2023)

Updated

NovaBridge Biosciences' Current Deferred Revenue came in at $305,552 for Q4 2023, down 75.0% from $1.22 million a year earlier.

Analysis

NovaBridge Biosciences (NBP) Current Deferred Revenue (2018 - 2023) Analysis & Trends

At the end of FY2023, NovaBridge Biosciences' Current Deferred Revenue was $310,000, down 75.4% from FY2022.

  • Current Deferred Revenue carries a five-year compound annual growth rate of -3.9% (FY2018 to FY2023).
  • Going back by year, Current Deferred Revenue was $1.26 million in FY2022 (-96.4%), $35.15 million in FY2021, $1.15 million in FY2020 (+104.4%) and $563,000 in FY2019 (+48.7%).
  • The Q4 2023 figure represents the lowest quarterly Current Deferred Revenue since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 NovaBridge Biosciences 131.20 Mn -664.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 309,553.96
Jun 30, 2023 1.46 Mn
Dec 31, 2022 1.25 Mn
Dec 31, 2021 35.15 Mn
Dec 31, 2020 1.15 Mn
Sep 30, 2020 453,000.00
Dec 31, 2018 2.06 Mn
API Access

NovaBridge Biosciences Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NBP&period=max&api_key=YOUR_API_KEY